FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns the use of synthetic tetrapeptide Ac-His-Ala-Glu-Glu-NH2 with an N-terminal acetyl group and a C-terminal amide group (HAEE) or pharmaceutically acceptable salts thereof, or complexes for restoring the function of human neurons to secrete a physiologically active chemical substance (4S, 7S, 10S, 13S)-4-((1H-imidazol-4-yl)methyl)-13-carbamoyl-10-(2-carboxyethyl)-7-methyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazagexadecane-16-acid (SRFM).
EFFECT: invention provides the possibility of restoring the function of neurons in neurodegenerative disorders associated with partial or complete loss of human neurons of the ability to secrete SRFM, which leads to a strong drop in the blood SRFM level compared to the physiological norm or complete cessation of SRFM secretion.
16 cl, 2 dwg, 9 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYNTHETIC TETRAPEPTIDE HAEE AND DERIVATIVES THEREOF INTENDED FOR PROTECTION OF HUMAN NEURON FUNCTION | 2023 |
|
RU2822602C1 |
| PHYSIOLOGICALLY ACTIVE SUBSTANCE SRFM AS BLOOD BIOMARKER FOR DIAGNOSING HUMAN NEURODEGENERATIVE DISORDERS AND DISEASES | 2023 |
|
RU2822604C1 |
| HAEE PEPTIDE MAGNESIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784746C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| HAEE PEPTIDE COPPER COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784732C1 |
| PEPTIDE CALCIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2785354C1 |
| HAEE PEPTIDE ZINC COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784319C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
| SODIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784326C1 |
| AMMONIUM SALT OF HAEE PEPTIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784249C1 |
